Miromatrix Medical Inc.

Article preview from Start Up- October, 2010

Regenerative medicine start-up Miromatrix Medical is working to commercialize a technology known as perfusion decellularization. Its proprietary, patent-protected technology involves the decellularization of any vascularized tissue, up to and including whole organs, leaving behind a completely preserved native scaffold (matrix) that retains the original architecture, mechanical properties and vascular network of the tissue or organ. This scaffold can then be repopulated with vascular- and organ-specific regenerative cells and, under controlled conditions in a bioreactor, a biocompatible, functioning organ or tissue is created.

Miromatrix Medical Inc.

Article preview from Start Up- October, 2010

Roughly 100,000 people in the US are currently awaiting a heart, lung, kidney, liver or other organ transplant, more than one million die each year from organ failure, and millions live with failing organs. What if it were possible for every one of these people, and others across the world, to receive a new functional organ, and at the same time save health care costs?

That is the goal of regenerative medicine start-up Miromatrix Medical Inc., which is working to commercialize a technology known as perfusion decellularization. Its proprietary, patent-protected technology involves the decellularization of any vascularized tissue, up to and including whole organs, leaving behind a completely preserved native scaffold (matrix) that retains the original architecture, mechanical properties and vascular network of the tissue or organ. This scaffold can then be repopulated with vascular- and organ-specific regenerative cells and, under controlled conditions in a bioreactor, a biocompatible, functioning organ or tissue is created.

The potential of this technology is what led 30-year pharmaceutical and medical device industry executive Robert Cohen to join the company as president and CEO in November 2009. "We're using a matrix that is so recognizable to cells that when new cells are added to the matrix, they know exactly what to do. All the things that they need to survive.

Purchase this article online or get it FREE when you subscribe to Start Up

Elsevier Business Intelligence announces the publication of a new Special Report "Bigger, Tougher,Faster"- Preparing for the New FDA. When the inspector comes calling ... will you be ready?

This 16-page report originally published in "The Silver Sheet". Learn more... 
About Start Up

No publication reviews leading edge companies and technology better than START-UP. Each issue of START-UP profiles the most important new product companies, identifies the hottest technology areas, reviews funds flowing into private companies and investment trends, and reports on university tech transfer licensing. Industries covered: pharmaceuticals, biotechnology, medical equipment & devices, and in vitro diagnostics.

Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985 9512